PAX8 (M)

Concentrated and Prediluted Monoclonal Antibody 902-438-040921



Available Product Formats				
Format	Catalog Number	Description	Dilution	Diluent
Concentrate	ACR 438 A, B, C	0.1, 0.5, 1.0 mL	1:100	Renoir Red
Predilute	APR 438 AA	6.0 mL	Ready-to-use	N/A
Q Series – For Leica BOND-III	ALR 438 G7	7.0 mL	Ready-to-use	N/A

Intended Use:

For Research Use Only. Not for use in diagnostic procedures.

Summary and Explanation:

PAX8 is a member of the paired box (PAX) family of transcription factors. Members of this gene family typically encode proteins which contain a paired box domain, an octapeptide, and a paired-type homeodomain. This family plays critical roles during fetal development and cancer growth. PAX8 is involved in kidney cell differentiation, thyroid development, or thyroid dysgenesis.

PAX8 is expressed in a high percentage of renal cell carcinomas and ovarian cancers. This mouse monoclonal PAX8 antibody [BC12] has been designed to target a restricted epitope and exhibits higher specificity and provides sharper staining than the PAX8 rabbit polyclonal antibody. Unlike the polyclonal PAX8, this mouse monoclonal antibody does not stain B-cells, and does not recognize epitopes of pancreatic origin and neuroendocrine cells in stomach and colon; thus providing superior specificity. The expression of the mouse monoclonal PAX8 target antigens was found in normal kidney, thyroid and cervix, but was not identified in normal ovary. By Western blot, [BC12] has been shown to recognize PAX8 and not PAX2, PAX5 or PAX6 proteins. PAX8 stains nuclei exclusively and performs well in formalin-fixed paraffin-embedded

U.S. Patents 8,852,592, 9,417,243, and patents pending.

Principle of Procedure:

Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. A secondary antibody may be applied to bind the primary antibody, followed by an enzyme labeled polymer; or an enzyme labeled polymer may be applied directly to bind the primary antibody. The detection of the bound primary antibody is evidenced by an enzyme-mediated colorimetric reaction.

Source: Mouse monoclonal

Species Reactivity: Human, mouse, rat, cat and dog

Clone: BC12 Isotype: IgG1

Protein Concentration: Call for lot specific IgG concentration.

Epitope/Antigen: PAX8 Cellular Localization: Nuclear

Positive Tissue Control: Normal kidney, renal cell or serous ovarian

carcinomas

Known Applications:

Immunohistochemistry (formalin-fixed paraffin-embedded tissues) Supplied As: Buffer with protein carrier and preservative

Storage and Stability:

Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

Staining Protocol Recommendations (intelliPATH FLX® and manual use):

Peroxide Block: Block for 5 minutes with Peroxidazed 1.

Pretreatment: Perform heat retrieval using Diva or Reveal Decloaker. Refer to the Diva or Reveal Decloaker product data sheet for specific instructions.

Biocare Medical

60 Berry Drive Pacheco, CA 94553

USA

Background Punisher. Primary Antibody: Incubate for 30-60 minutes at RT.

Staining Protocol Recommendations (intelliPATH FLX and

Protein Block (Optional): Incubate for 5-10 minutes at RT with Probe: Incubate for 10 minutes at RT with a secondary probe.

Polymer: Incubate for 10-20 minutes at RT with a tertiary polymer. Chromogen:

manual use) Cont'd:

Incubate for 5 minutes at RT with Biocare's DAB - OR - Incubate for 5-7 minutes at RT with Warp Red.

Counterstain:

Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha's Bluing Solution for 1 minute. Rinse with deionized water.

Technical Note:

- 1. Counterstain lightly with hematoxylin as over-staining may mask stained nuclei, especially in clear cell RCC.
- 2. This antibody, for intelliPATH FLX and manual use, has been standardized with MACH 4 detection system. Use TBS for washing steps.

Staining Protocol Recommendations (Q Series - For Leica BOND-III):

ALR438 is intended for use with the Leica BOND-III. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

Protocol Name: IHC Protocol F **Detection:** Bond Polymer Refine

HIER: 20 min with ER2 Peroxide Block: 5 min

Marker (Primary Antibody): 15 min

Post Primary: 8 min Polymer: 8 min Mixed DAB Refine: 10 min Hematoxylin: 5 min

Limitations:

This product is provided for Research Use Only (RUO) and is not for use in diagnostic procedures. Suitability for specific applications may vary and it is the responsibility of the end user to determine the appropriate application for its use.

Precautions:

- 1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN3) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (8)
- 2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (9)

Rev: 062117

PAX8 (M)

Concentrated and Prediluted Monoclonal Antibody 902-438-040921



Precautions Cont'd:

- 3. Microbial contamination of reagents may result in an increase in nonspecific staining.
- 4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.
- 5. Do not use reagent after the expiration date printed on the vial.
- 6. The SDS is available upon request and is located at http://biocare.net. **Technical Support:**

Contact Biocare's Technical Support at 1-800-542-2002 for questions regarding this product.

References:

- 1. Tacha D, *et al.* PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin. Appl Immunohistochem Mol Morphol. 2013 Jan; 21(1): 59-63.
- 2. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):293-9.
- 3. Lotan TL, *et al.* Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. Am J Surg Pathol. 2009 Jul; 33(7):1037-41.
- 4. Viktorová T, *et al.* Expression of PAX2 and PAX8 genes in conventional type of renal carcinoma and their role in the tumor prognosis. Diagn Cytopathol. 2008 Aug; 36(8):568-73.
- 5. Narlis M, *et al.* Pax2 and Pax8 regulate branching morphogenesis and nephron differentiation in the developing kidney. J Am Soc Nephrol. 2007 Apr; 18(4):1121-9.
- 6. Moretti L, *et al.* N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas. Mod Pathol. 2012 Feb;25(2):231-6.
- 7. Lorenzo PI, et al. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors. Histochem Cell Biol. 2011 Nov;136(5):595-607. 8. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 "Decontamination of Laboratory Sink Drains to Remove Azide Salts."
- 9. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.
- Q Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare antibodies by Leica Biosystems. Biocare and Leica Biosystems are not affiliated, associated or related in any way. Leica, Leica Biosystems, BOND-MAX and BOND-III are trademarks of Leica Biosystems.



Pacheco, CA 94553

USA

Rev: 062117

Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080